Immunoprecise Antibodies Ltd IPA

Healthcare Biotechnology

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.

NDAQ:IPA - Post by User

Immunoprecise Antibodies Ltd

<< Previous

Bullboard Posts

Next >>

Post by AveragePennyon Mar 08, 2022 11:28am

120 Views

Post# 34495447

ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial

Investors interested in submitting questions ahead of the call are encouraged to email John Mullaly of LifeSci Advisors, the Company’s investor relations contact.

Earnings Call Details:

Date: March 16, 2022
Time: 10:30 a.m. Eastern time
Toll-free dial-in number: 1-877-407-3982
International dial-in number: 1-201-493-6780
Conference ID: 13727621
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1534157&tp_key=1be5e34d32
The conference call will be webcast live and available for replay via a link provided in the Investors section of the company’s website at https://www.immunoprecise.com/investors/.

https://www.businesswire.com/news/home/20220308005501/en/